Literature DB >> 17305509

Role of cathepsin K in normal joints and in the development of arthritis.

H J Salminen-Mankonen1, J Morko, E Vuorio.   

Abstract

Cysteine cathepsins are a large family of proteolytic enzymes active at acidic pH as found in lysosomes. Since its discovery in 1990's, cathepsin K has been shown to be a key enzyme in osteoclastic bone resorption through its activity in the resorption lacuna. Although characteristic to osteoclasts, the expression of cathepsin K has also been observed at other sites in skeleton. Several recent observations have demonstrated up-regulation of cathepsin K in osteoarthritic cartilage and inflamed synovial tissue. As cathepsin K is one of the few extracellular proteolytic enzymes capable of degrading native fibrillar collagen, it may play an important role in the progressive destruction of articular cartilage both in osteoarthritis and in inflammatory arthritides. Also transgenic mouse models have provided evidence supporting the important role of cathepsin K in both groups of arthritides. The aim of this chapter is to review the accumulating evidence for the role of cathepsin K in degradation of articular cartilage regardless of its pathogenic background, and to discuss the potential efficacy of cathepsin K inhibitors to slow down or prevent articular cartilage degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305509     DOI: 10.2174/138945007779940188

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  38 in total

Review 1.  Pharmacologic therapy for osteoarthritis--the era of disease modification.

Authors:  David J Hunter
Journal:  Nat Rev Rheumatol       Date:  2010-11-16       Impact factor: 20.543

Review 2.  Are there promising biologic therapies for osteoarthritis?

Authors:  David J Hunter
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

3.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

4.  Trichostatin A inhibits expression of cathepsins in experimental osteoarthritis.

Authors:  Wei-Ping Chen; Jia-Peng Bao; Jin-Li Tang; Peng-Fei Hu; Li-Dong Wu
Journal:  Rheumatol Int       Date:  2011-10       Impact factor: 2.631

Review 5.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Authors:  Yanwen Qin; Guo-Ping Shi
Journal:  Pharmacol Ther       Date:  2011-05-12       Impact factor: 12.310

Review 6.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

7.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

8.  Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.

Authors:  Dorothea Piecha; Jürgen Weik; Heike Kheil; Gabriele Becher; Andreas Timmermann; Andreas Jaworski; Maren Burger; Michael W Hofmann
Journal:  Inflamm Res       Date:  2009-11-10       Impact factor: 4.575

Review 9.  Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Authors:  Dieter Brömme; Fabien Lecaille
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

Review 10.  Proteomics of the lysosome.

Authors:  Torben Lübke; Peter Lobel; David E Sleat
Journal:  Biochim Biophys Acta       Date:  2008-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.